The Global Program Lead (GPL) will serve as the point of accountability for two hematology assets. The program includes a growing marketed asset for anemia with ongoing pivotal studies and a potential first‑in‑class CELMoD for sickle cell disease. The GPL is responsible for leading the Global Program Teams and orchestrating the design and execution of a global integrated program strategy from candidate nomination through drug development to successful launch and commercialization, including related disease area strategies (e.g., AML).